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Abstract 
 
Sleep restriction is associated with impaired glucose regulation, which is a risk 
factor for developing type 2 diabetes. However, the underlying mechanisms 
leading to this impairment are unknown. This thesis aims to examine the effects 
of partial sleep restriction on whole body metabolism, and investigate whether 
the impairment in insulin sensitivity observed after sleep restriction is coupled 
with changes in systemic inflammation and skeletal muscle insulin signalling. 
A pilot study was carried out to assess whether or not two nights of partial sleep 
restriction would alter glucose regulation and substrate utilisation. 10 healthy 
males then participated in a separate randomised crossover study involving two 
nights of habitual sleep (control) and two nights of 50% of habitual sleep (sleep 
restriction). An oral glucose tolerance test was carried out after the second night 
of each condition to assess whole body glucose tolerance, insulin sensitivity and 
inflammation, and to examine skeletal muscle insulin signalling. 
The pilot study findings confirmed that two nights of partial sleep restriction 
impaired glucose tolerance. Findings from the main study revealed no effect of 
trial on glucose tolerance (P = .222). Insulin sensitivity estimated by the Matsuda 
Index was 18.6% lower in the sleep restriction condition (P = .010). CRP and TNFα 
were similar between trials (P > 0.05). Fold change in PKB activity from baseline 
tended to be lower following sleep restriction at 30 min (P = .098) and 120 min (P 
= .087). AUC for insulin to PKB index was significantly higher in the sleep 
restriction condition (P = .012). Phosphorylated to total PKB was similar between 
conditions (P = .217). 
Two nights of sleep restriction decreased insulin sensitivity in healthy males. This 
impairment was not coupled by increased systemic inflammation. Skeletal 
muscle insulin signalling showed conflicting findings, suggesting a possible 
disruption of skeletal muscle insulin signalling.  
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Chapter 1 
Introduction 
 
In modern society many individuals often voluntarily curtail sleep due to 
increasing work or lifestyle demands (Luyster et al., 2012). Despite a 
recommended sleep duration of 7 to 9 hours each night, a recent report by The 
Sleep Council (2013) revealed that 70% of adults in the United Kingdom sleep for 
less than 7 hours per night, with an increasing number sleeping for only 5 to 6 
hours each night. The reduction in sleep duration over the past few decades has 
been paralleled with an increased prevalence of type 2 diabetes and impaired 
glucose tolerance. This raises the possibility that there may be a connection 
between sleep duration and risk of developing diabetes. Indeed, research has 
shown that reduced sleep is associated with an increased risk of type 2 diabetes 
(Yaggi et al., 2006), which is a disorder characterised by insulin resistance and 
impaired glucose control. Both epidemiological and experimental studies 
(Knutson et al., 2007) provide evidence for impaired glucose control and insulin 
sensitivity after a period of sleep restriction. These data support the notion that 
there is a link between decreased sleep duration and an increased risk of 
impaired metabolism.  
However, little is known about the underlying mechanisms. One plausible 
mechanism could be a dysfunction of glucose uptake in the peripheral tissues. 
This thesis is supported by evidence demonstrating decreased peripheral insulin 
sensitivity after sleep loss (Donga et al., 2010; Rao et al., 2015). Adipose tissue 
signalling has previously been shown to be affected by sleep restriction 
(Broussard et al., 2012). However, there are currently no published studies which 
examine glucose regulation in skeletal muscle after sleep restriction. Skeletal 
muscle accounts for approximately 80% of glucose uptake under insulin-
stimulated conditions (Thiebaud et al., 1982), suggesting that it may be a key 
target for impaired glucose regulation following sleep loss. Therefore, research 
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investigating the responsiveness of insulin signalling pathways within skeletal 
muscle after sleep restriction is warranted. 
The mechanisms responsible for impaired peripheral insulin sensitivity are 
unclear, however a number of factors have been proposed including alterations 
in autonomic function, hormonal profiles, and systemic inflammation 
(Mullington et al., 2009). Research shows increased levels of inflammation after 
sleep restriction (Vgontzas et al., 2004). Increased inflammation can induce 
insulin resistance (Shoelson et al., 2006), so it can be hypothesised that an 
increase in inflammation may also contribute to impaired insulin sensitivity 
following sleep restriction. 
The general aim of this thesis is to explore the impairment of glucose regulation 
brought about by voluntary sleep curtailment. Specifically, the aims of the 
current project are to assess the effects of partial sleep restriction on: 
(a) whole-body glucose tolerance and insulin sensitivity,  
(b) skeletal muscle insulin signalling, and  
(c) systemic inflammation.  
It is hypothesised that sleep restriction will lead to impaired whole body glucose 
tolerance and insulin sensitivity, and that this will be coupled with changes in 
skeletal muscle insulin signalling and an increase in systemic inflammation. 
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Chapter 2 
Literature Review 
2.1 – Overview of sleep 
2.1.1 – The function of sleep 
Originally believed to be of primary importance for brain function and memory, 
more recent research has demonstrated an important role of sleep in many 
other aspects of physiological health including energy conservation, immune 
function, appetite, and metabolism (Berger and Phillips, 1995; Irwin, 2002; Killick 
et al., 2012). During sleep, physiological changes occur in several different 
systems including cardiovascular, respiratory and endocrine changes. These 
changes alter many processes within the body, including cytokine expression and 
glucose metabolism.  
Sleep deprivation studies have demonstrated that altering the normal sleep-
wake pattern disrupts the diurnal pattern of immune function (Dickstein and 
Moldofsky, 1999), which may interfere with host defence mechanisms. Similarly, 
disruptions in glucose metabolism have been demonstrated when sleep is 
altered (Morselli et al., 2010). Taken together, it is apparent that sleep has a vital 
role in many biological processes and is not solely for cognitive function, as was 
thought previously. 
2.1.2 – Sleep architecture 
A period of sleep consists of cycles which tend to last approximately 70 to 90 
minutes each (Feinberg and Floyd, 1979). Sleep cycles are comprised of rapid eye 
movement (REM) sleep and non-rapid eye movement (NREM) sleep. NREM sleep 
is subdivided into four stages – N1, N2, N3 and N4. N1 sleep occurs at the onset 
of sleep, followed by N2, N3, N4, and then REM sleep (Carskadon and Dement, 
2011). These stages repeat for approximately 4 to 6 cycles throughout the night, 
depending on the total sleep time (Reutrakul and Van Cauter, 2014). During each 
cycle the percentage of each stage differs, with NREM sleep being predominant 
during the earlier cycles and decreasing as sleep progresses (Sharma and Kavuru, 
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2010). The deepest stage of sleep, N3, is often referred to as slow wave sleep 
and tends to decline as an individual ages (Van Cauter et al., 2000). 
2.1.3 – Methods of measuring sleep duration 
Several methods of measuring sleep variables exist including objective measures 
such as Polysomnography and actigraphy as well as subjective measures such as 
sleep diaries. Polysomnography (PSG) is considered the gold standard 
measurement method. PSG assesses a number of physiological parameters 
including brain activity and bodily movements to determine sleep architecture 
(Marino et al., 2013). Such measurements yield a great amount of detail 
throughout the sleep period including duration of individual sleep stages and 
total sleep time amongst others. Whilst PSG can provide an extremely detailed 
evaluation of sleep, it often requires the individual to sleep in a sleep laboratory 
so is less applicable to longitudinal or field based studies. Sleeping in an 
unfamiliar environment, such as a sleep laboratory, may disrupt sleep and may 
not necessarily reflect the sleep quality achieved in the home environment. 
Other methods of evaluating sleep have been developed which are more 
practical for use in field and longitudinal studies. Actigraphy is a commonly used 
objective measurement of sleep which has been shown to have an accuracy and 
sensitivity in excess of 80% and 90%, respectively, when compared to 
polysomnography (Marino et al., 2013; Slater et al., 2015). Total sleep time 
estimated from actigraphy is also strongly correlated with PSG (r = 0.79 to r = 
0.94) (Jean-Louis et al., 2001). Actigraphy involves estimation of sleep 
parameters from tri-axial movement. Although sleep architecture such as 
individual sleep stages cannot be determined using actigraphy; this method 
provides a reliable, objective measurement of sleep variables and may be an 
appropriate method for measuring sleep in settings where polysomnography is 
not feasible.  
Sleep diaries are often used as a subjective measure of sleep either as a stand-
alone measurement or in conjunction with an objective measurement. The 
completion of a sleep diary can allow estimation of quality of sleep as well as 
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estimating periods of wakefulness during the night, which may not always be 
detected by actigraphy. Self-reported measures of sleep contain an inherent risk 
of under- or over-reporting, whether purposely or not. Thus, using an objective 
measure, such as actigraphy, in combination with a sleep diary may address the 
limitations of each method. Actigraphy and sleep diaries can therefore provide a 
useful overview of sleep characteristics in studies where there is no access to 
PSG. 
 
2.2 – Glucose regulation during sleep 
Glucose regulation exhibits diurnal variations due to circadian rhythmicity (Van 
Cauter et al., 1997). Typically, glucose tolerance decreases as the day progresses, 
reaching a minimum during the first half of the night. However, differences in 
glucose tolerance also occur during sleep when compared to a state of 
wakefulness (Van Cauter et al., 1997). Glucose concentrations and insulin 
secretion rates have been observed to increase during sleep in the daytime as 
well as at night, indicating altered glucose regulation during sleep, independent 
of time of day (Van Cauter et al., 1991). During sleep, systemic glucose utilisation 
is reduced, primarily due to a decrease in brain glucose metabolism (Boyle et al., 
1994). Therefore, when taken together, it is apparent that sleep is important for 
many aspects of glucose regulation, thus any alterations in sleep characteristics 
are likely to impact normal glucose regulation. 
 
2.3 – Sleep duration and disease – Epidemiological studies  
Epidemiological data has shown an association between both short and long 
sleep duration and an increase in mortality (Cappuccio et al., 2010). Compared to 
individuals achieving 7 to 9 hours of sleep, short sleepers have a 12% increased 
risk of early all-cause mortality (Cappuccio et al., 2010). This increased risk 
appears to be consistent across a range of populations including younger and 
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older adults, as well as individuals from a variety of geographical locations and 
ethnic backgrounds. 
In addition to an increased risk of mortality, individuals with short sleep 
durations may have a higher risk of developing chronic diseases. The risk of 
developing cardiovascular disease is increased in individuals habitually sleeping 
less than 7 hours (Sabanayagam and Shankar, 2010). The odds of developing 
cardiovascular disease were increased when comparing six hours to seven hours 
of sleep, and increased even further for sleep durations of five hours or less. 
Similarly, short sleep durations are also linked to an increased risk of metabolic 
diseases (Yaggi et al., 2006; Gottlieb et al., 2005; Gangwisch et al., 2007). 
Epidemiological data have established a link between short sleep duration and 
increased risk of type 2 diabetes. The risk of developing type 2 diabetes has been 
shown to be more than doubled in those sleeping 5 hours or less compared to 7 
hours, even when confounding variables were accounted for (Yaggi et al., 2006; 
Mallon et al., 2005). Interestingly, the increased risk appears to be sex specific. 
Several studies which have included only females, or which have categorised 
results by sex, have found that the risk of developing diabetes does not appear 
to be increased by short sleep durations in females (Ayas et al., 2003; Mallon et 
al., 2005). Why an increased risk occurs in males but not females remains 
unknown. Further research investigating the effects of short sleep specifically in 
females is warranted. 
These data demonstrating an increased risk of developing type 2 diabetes in 
short sleep durations are consistent with laboratory studies which have 
repeatedly shown a relationship between sleep restriction and impaired 
metabolism. The increased risk of developing type 2 diabetes, an illness 
characterised by metabolic dysfunction leading to resistance to the actions of 
insulin, may cause a disruption to glucose homeostasis, and subsequently, lead 
to a myriad of health complications. 
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2.4 – Acute sleep restriction and impaired glucose clearance 
Upon ingestion, glucose enters the bloodstream and must be taken up by cells in 
order to be utilised or stored for future use. However, the rate of glucose 
clearance can be impacted by sleep restriction. Six nights of 4 hours sleep was 
sufficient to decrease glucose clearance by almost 40% during an intravenous 
glucose tolerance test (IVGTT) in healthy males (Spiegel et al., 1999). Similarly, a 
decrease in glucose disposal during a hyperinsulinemic-euglycemic clamp has 
been demonstrated after just a single night of sleep restriction (Donga et al., 
2010). A decreased rate of glucose disposal is suggestive of disrupted peripheral 
insulin sensitivity, and may also affect energy metabolism and substrate use. 
 
2.5 – The relationship between sleep and resting metabolic rate and 
respiratory exchange ratio 
Energy conservation is a primary function of sleep (Berger and Phillips, 1995). 
Resting energy expenditure (REE) is lower during sleep than wakefulness (Jung et 
al., 2011). During a period of sleep deprivation, 24-hour energy expenditure is 
increased as well as 8-hour energy expenditure during the night of sleep 
deprivation compared to a period of normal sleep (Jung et al., 2011). Despite 
studies showing changes in resting energy expenditure during the night of sleep 
restriction, conflicting findings have been demonstrated with regards to energy 
expenditure in the morning following sleep restriction. Several studies have 
measured resting energy expenditure in the morning following sleep loss ranging 
from three nights to two weeks, and observed no differences compared to 
control or baseline sleep (Nedeltcheva et al., 2009; Buxton et al., 2010; St-Onge 
et al., 2011; Shechter et al., 2014; Rao et al., 2015). One study observed a 
reduction in REE in the morning (Benedict et al., 2011), however they utilised 
total sleep deprivation, suggesting that REE may be affected only by total rather 
than partial sleep restriction. 
Sleep may also impact metabolism by altering substrate utilisation. At present, 
studies investigating substrate utilisation after sleep loss are limited, particularly 
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in the fasted state. In those studies that have, two have observed a decrease in 
respiratory exchange ratio (RER) following partial sleep restriction (Klingenberg 
et al., 2012; Shechter et al., 2014), and one has reported no difference (St-Onge 
et al., 2011). In normal glucose tolerant subjects, plasma glucose concentrations 
are usually related to glucose utilisation, with a higher plasma glucose 
concentration leading to a higher rate of glucose utilisation (Doberne et al., 
1982). This concept would suggest that, in theory, if sleep restriction increases 
plasma glucose concentration, carbohydrate oxidation should also increase. The 
mixed findings regarding RER and substrate oxidation in these studies suggest 
that this may not always be the case, however additional research is warranted. 
 
2.6 – Impact of sleep restriction on insulin and glucose metabolism 
2.6.1 – Methods of measuring glucose tolerance and insulin sensitivity 
Research investigating glucose tolerance and insulin sensitivity typically uses one 
or more of the following techniques: hyperinsulinemic-euglycemic clamp, 
intravenous glucose tolerance test (IVGTT), or oral glucose tolerance test (OGTT). 
The method chosen depends on factors including the type of study, setting, and 
variables of interest.  
The hyperinsulinemic-euglycemic clamp is considered the gold standard 
technique for measuring insulin sensitivity (DeFronzo et al., 1979). This technique 
involves intravenous infusion of insulin and glucose to maintain a euglycemic 
state. Insulin sensitivity can be determined according to the rate of glucose 
infusion, and labelled glucose may be used to determine glucose regulation in 
specific tissues. Although the hyperinsulinemic-euglycemic clamp provides 
accurate measurements of insulin sensitivity in vivo, it can be expensive and 
impractical, therefore more feasible indirect methods of measuring insulin 
sensitivity and glucose tolerance have been developed. 
An IVGTT uses the minimal model to estimate insulin sensitivity from blood 
samples obtained at regular intervals following an intravenous glucose bolus 
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(Muniyappa et al., 2008). Insulin sensitivity can be calculated based on the rate 
of glucose disappearance. The minimal model IVGTT approach has the advantage 
of using dynamic rather than steady-state data and can give measures of glucose 
effectiveness and beta-cell function in addition to insulin sensitivity (Muniyappa 
et al., 2008). Although the IVGTT technique is more feasible than the clamp 
technique, it still requires many blood samples and an intravenous infusion, 
making it impractical and time-consuming in some circumstances. Other 
methods, such as the OGTT, are less complex and have better ecological validity 
than the IVGTT. 
The OGTT is a simpler test which can be used to estimate glucose tolerance and 
insulin sensitivity. A glucose drink is consumed and blood samples are drawn 
before and at regular intervals after the drink to determine measures of glucose 
tolerance and insulin sensitivity. The OGTT has been compared to the gold 
standard hyperinsulinemic-euglycemic clamp and has been shown to be a 
suitable estimate of glucose tolerance and insulin sensitivity (Matsuda and 
DeFronzo, 1999). As the OGTT is designed to assess glucose clearance, indexes 
have been developed to allow estimation of insulin sensitivity from this 
technique. The Matsuda Index (Matsuda and DeFronzo, 1999) and homeostatic 
model of assessment (HOMA) (Matthews et al., 1985) are widely used indices 
which can estimate insulin sensitivity. To calculate these indices the following 
equations are used: 
Matsuda index = 10000/square root[(fasting plasma glucose x fasting 
plasma insulin) x (mean glucose during OGTT x mean insulin during 
OGTT)]  
HOMA = (fasting glucose x fasting insulin)/22.5 
The Matsuda index tends to reflect changes at the whole-body level including 
both peripheral and hepatic insulin sensitivity whereas the HOMA uses only 
fasting glucose and insulin values and therefore primarily reflects hepatic insulin 
sensitivity (Abdul-Ghani et al., 2007). 
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Therefore, in studies requiring measurement of whole body insulin sensitivity, 
the Matsuda index provides a good estimate when the hyperinsulinemic-
euglycemic clamp is impractical. 
2.6.2 – Sleep restriction and glucose tolerance 
Spiegel and colleagues (1999) conducted the seminal study in the field, 
identifying an impairment in glucose metabolism following partial sleep 
restriction. Healthy young men were restricted to 4 hours sleep per night for 6 
nights during a sleep restricted condition, which was followed by a recovery 
condition of 12 hours in bed for 6 nights. When sleep restricted, individuals 
displayed decreased rates of glucose clearance and decreased glucose 
effectiveness during an IVGTT and an increased glucose response to a breakfast 
meal despite similar insulin concentrations. Spiegel et al. (1999) noted that the 
glucose tolerance values seen in the sleep restriction condition in their study 
reflected values which were typical of older adults or individuals with impaired 
glucose tolerance. This study clearly demonstrates an impairment in glucose 
tolerance in the sleep restriction condition. However, the applicability of the 
results in more ecologically valid conditions could be questioned due to the 
comparison of the sleep restriction condition to a sleep recovery condition of 12 
hours. Six nights of twelve hours sleep is likely unrealistic due to work and 
lifestyle demands. A comparison of sleep restriction to a sleep duration closer to 
the recommended duration of 7 to 8 hours would have been more ecologically 
valid. 
More recent studies have also investigated glucose metabolism following sleep 
restriction. Impairments in glucose tolerance have been observed in several of 
these studies (Nedeltcheva et al., 2009; Buxton et al., 2010; Donga et al., 2010; 
Reynolds et al., 2012). However, there are also studies in which glucose 
tolerance was unchanged following sleep restriction (Bosy-Westphal et al., 2008; 
Klingenberg et al., 2013; Wang et al., 2016). One notable difference between 
these studies showing conflicting results is the number of nights of sleep 
restriction. Those studies which found changes in blood glucose concentrations 
restricted sleep for at least 5 nights, whereas the studies which did not observe 
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any differences used less than 5 nights of sleep restriction. It can therefore be 
speculated that there may be a minimum number of nights or hours of sleep 
restriction that is required to impair glucose tolerance. Despite this, Donga and 
colleagues (2010), observed changes in glucose clearance after a single night of 
sleep restriction. It is possible that the hyperinsulinemic-euglycemic clamp used 
for measurement of glucose tolerance is more sensitive and may detect subtle 
changes when compared to OGTT and IVGTT. It is therefore possible that the 
method of measurement may have impacted the results, however to confirm 
this further research is needed.  
Another possibility as to why blood glucose concentrations remain unchanged in 
some studies may be due to an increased production of insulin. Glucose is tightly 
regulated, and often, additional insulin is produced in order to maintain 
homeostasis (DeFronzo and Tripathy, 2009). In many cases despite no obvious 
changes in glucose concentrations, an impairment in glucose metabolism may 
still be present and could be determined by measuring plasma insulin 
concentrations. This is demonstrated by Wang and colleagues (2016) who found 
no changes in plasma glucose concentrations during the OGTT following sleep 
restriction, however area under the curve for plasma insulin was higher, 
indicating an impairment in glucose metabolism.  
2.6.3 – Sleep restriction and insulin sensitivity  
Reduced insulin sensitivity is consistently found following sleep restriction 
(Nedeltcheva et al., 2009; Buxton et al., 2010; Donga et al., 2010; Broussard et 
al., 2012; Klingenberg et al., 2013; Rao et al., 2015; Wang et al., 2016). This 
finding is evident across a range of different methodologies, including IVGTT 
derived insulin sensitivity (Nedeltcheva et al., 2009; Buxton et al., 2010; 
Broussard et al., 2012), insulin sensitivity assessed by hyperinsulinemic 
euglycemic clamp (Donga et al., 2010; Rao et al., 2015) and insulin sensitivity 
determined by the Matsuda index following an OGTT (Klingenberg et al., 2013; 
Wang et al., 2016). However, the varying severities of sleep restriction and 
methods of measurement make direct comparisons difficult. Nevertheless, the 
mutual finding of reduced insulin sensitivity suggests that glucose homeostasis is 
22 
 
sensitive to even mild reductions in sleep duration, for example 1 to 3 hours of 
restriction each night (Wang et al., 2016).  
Hepatic and peripheral insulin sensitivity are both affected by sleep restriction. A 
single night of 4.5 hours sleep restriction can reduce hepatic and peripheral 
insulin sensitivity by 22% and 20%, respectively (Donga et al., 2010). Recent 
research supports the reduction in peripheral insulin sensitivity (Broussard et al., 
2012; Rao et al., 2015), however conflicting results have been observed 
regarding hepatic insulin sensitivity (Rao et al., 2015). It is unclear why these 
conflicting findings exist, although, as discussed previously, the severity of sleep 
restriction may be a contributing factor. The underlying mechanisms leading to a 
reduction in insulin sensitivity in the studies are unknown, so it can be 
speculated that these mechanisms differ depending on the severity of sleep 
restriction. Further study is therefore warranted to investigate the causes of 
insulin resistance following both acute and chronic sleep loss. 
 
2.7 – Potential mechanisms underlying impaired glucose metabolism following 
sleep restriction 
It is clear that acute sleep restriction leads to changes in glucose regulation 
which may have the potential to increase the risk of type 2 diabetes in 
individuals with chronic sleep loss. Before any interventions to prevent the 
increased risk of developing impaired glucose regulation can be developed, it is 
first necessary to identify the mechanisms which link sleep loss to these changes 
in metabolism. However, at present our understanding of these mechanisms 
remains elusive. Several theories as to why glucose metabolism is altered 
following sleep restriction have been proposed, including changes in autonomic 
function and hormone secretion (Mullington et al., 2009), increased 
inflammation (Mullington et al., 2010), and development of peripheral insulin 
resistance (Broussard et al., 2012; Rao et al., 2015). The underlying mechanisms 
are likely multifactorial and thus both of these proposed theories may be 
involved. It can be speculated that the mechanism of impairment could differ 
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depending on factors such as gender, age and even sleep restriction protocol. 
However, studies addressing the underlying mechanisms are limited, and in 
those that have findings are inconsistent, particularly regarding inflammation. 
2.7.1 – Insulin signalling in peripheral tissues following sleep restriction 
In the postprandial state the majority of glucose disposal occurs in the peripheral 
tissues (Woerle et al., 2003), therefore it seems sensible to hypothesise that an 
impairment in insulin sensitivity in peripheral tissues may be influential in the 
impaired whole body regulation following sleep restriction. Indeed, several 
laboratory studies have shown peripheral insulin resistance after sleep loss 
(Donga et al., 2010, Rao et al., 2015). Insulin signalling in adipocytes was 
investigated following four nights of partial sleep restriction in healthy 
individuals (Broussard et al., 2012). In addition to reduced whole body insulin 
sensitivity, they demonstrated an impairment in insulin signalling, manifested by 
a reduction in phosphorylation of protein kinase B (PKB).  
In adipose and skeletal muscle tissue cells, PKB is key to the insulin signalling 
pathway. When insulin binds to the insulin receptors on the cell membrane, the 
insulin signalling pathway begins, ultimately leading to translocation of GLUT4 to 
the cell membrane (Zhang and Liu, 2014). This translocation of GLUT4 to the 
membrane facilitates glucose uptake into the cell. PKB is a key mediator in this 
pathway, therefore these data suggest that an impairment in insulin signalling in 
adipose tissue may contribute to the impairment in whole body glucose 
regulation.  
Whilst adipose tissue is an important component of glucose control, it is likely 
that other peripheral tissues, such as skeletal muscle, may also be involved. 
Given that skeletal muscle is responsible for up to 80% of glucose uptake under 
insulin-stimulated conditions (Thiebaud et al., 1982), it can be theorised that a 
defect in skeletal muscle insulin signalling may promote impaired whole body 
glucose control following sleep loss. Peripheral insulin resistance, specifically in 
skeletal muscle, is thought to be the initial defect in the development of type 2 
diabetes (DeFronzo and Tripathy, 2009). If sleep restriction leads to skeletal 
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muscle insulin resistance, this may explain the reduction in insulin sensitivity in 
acute sleep restriction studies; and may also explain the higher risk of type 2 
diabetes which is shown in individuals who display chronic short sleep 
characteristics. At present there are no published studies investigating skeletal 
muscle insulin signalling after acute sleep restriction. 
2.7.2 – Inflammation, insulin resistance, and sleep restriction 
Chronic low-level inflammation is often present in individuals with insulin 
resistance (Shoelson et al., 2006). Sleep restriction has the potential to increase 
inflammatory processes (Irwin, 2002), which may contribute to the decrease in 
insulin sensitivity observed following sleep loss. A number of inflammatory 
markers that are associated with sleep restriction include interleukin-6 (IL-6), 
tumour necrosis factor alpha (TNF-α), and C-reactive protein (CRP) (Meier-Ewert 
et al., 2004; Vgontzas et al., 2004). Additionally, activation of the inflammatory 
regulator, NF-B is higher in peripheral blood mononuclear cells following a 
single night of sleep restriction (Irwin et al., 2008).  
Increased inflammation may lead to insulin resistance through a variety of 
mechanisms. TNF-alpha can increase serine phosphorylation of IRS-1, which 
reduces tyrosine phosphorylation and disrupts insulin signalling, thus promoting 
insulin resistance (Kanety et al., 1995). IL-6, another inflammatory marker which 
has been observed to increase after sleep restriction, can impact insulin 
signalling by also targeting IRS-1 (Chen et al., 2015). In addition, GLUT4 
expression is reduced by IL-6, which will result in decreased glucose uptake into 
cells (Chen et al., 2015). Both TNF-α and IL-6 can regulate CRP (Castell et al., 
1990), suggesting that the higher concentrations of CRP following sleep 
restriction may be a result of increases in other inflammatory markers. Levels of 
NF-B activation are also related to the presence of other inflammatory markers. 
Often, the activation of the NF-kB pathway is regulated by TNF-α (Lawrence, 
2009). Hence, the increase in TNF-α observed after sleep restriction may be 
responsible for the heightened activation of NF-B. 
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Since sleep restriction leads to increased inflammation, it is possible that 
inflammation promotes insulin resistance through a disturbance in insulin 
signalling. However, there is a lack of studies which have measured glucose 
metabolism and levels of inflammation in response to sleep restriction in the 
same study. So whilst we can hypothesise that there is a link, we cannot be 
certain until more research has been carried out. 
2.7.3 – Stress hormones and sleep restriction 
Another mechanism which has been proposed to contribute to impaired glucose 
metabolism following sleep restriction is an alteration in the secretion of the 
stress hormone cortisol. Evening cortisol concentrations are often increased 
following sleep restriction (Spiegel et al., 1999; Buxton et al., 2010; Reynolds et 
al., 2012). However, many studies have demonstrated no differences in morning 
and 24 hr cortisol between sleep restriction and control conditions (Vgontzas et 
al., 2004; Donga et al., 2010; Leproult et al., 2011; Schmid et al., 2011). It can 
therefore be suggested that increased cortisol may not be one of the primary 
underlying mechanisms leading to the impairment in glucose regulation 
following sleep restriction. 
2.8 – Conclusions 
This literature review covers many important aspects relating to sleep restriction 
and glucose metabolism. Whilst the wide variety of protocols make comparisons 
between studies difficult, there is a clear consensus that sleep is vital in glucose 
homeostasis, and that insufficient sleep can induce a wide variety of changes 
relating to glucose metabolism. However, whilst these ideas are consistent 
among the literature, the review raises several questions which need to be 
addressed to obtain a more complete understanding of the impact of sleep on 
glucose metabolism. 
Arguably the most important question raised is what is causing the impairment 
in glucose metabolism following sleep restriction? Whilst several underlying 
mechanisms are beginning to be investigated, there is still much to uncover in 
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this area. Inflammation and peripheral insulin signalling appear likely to be 
involved, but evidence is lacking. 
As an impairment in glucose metabolism increases the risk of developing type 2 
diabetes, research to investigate the underlying mechanisms is warranted to gain 
a better understanding of why sleep restriction impacts glucose metabolism. This 
will then aid the development of interventions to alleviate the negative impacts 
of short sleep on glucose metabolism, and prevent an increase in the risk of type 
2 diabetes.  
The studies in this thesis are designed to further explore the relationship 
between sleep restriction and impaired glucose regulation and, more specifically, 
investigate whether the impairment in glucose regulation observed after sleep 
restriction is accompanied by changes in systemic inflammation and skeletal 
muscle insulin signalling. Two nights of sleep restriction are compared to two 
nights of control sleep in healthy individuals. Whole body glucose tolerance, 
insulin sensitivity, and systemic inflammation are measured from blood samples 
obtained during an OGTT following the second night of each condition. Collection 
of muscle tissue samples also allows skeletal muscle insulin signalling to be 
investigated. The findings of these studies will aid in understanding the 
underlying mechanisms and give scope for further work in the area.  
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Chapter 3  
Acute sleep restriction reduces glucose tolerance and alters fasted substrate 
metabolism in healthy males: a pilot study 
3.1 – Introduction 
Short sleep is linked to a disruption in glucose metabolism (Knutson et al., 2007). 
Understanding the link between short sleep and impaired glucose metabolism is 
of importance to acute and chronic metabolic health (Knutson and Van Cauter, 
2008). The studies investigating this topic vary widely in the methodology used. 
Sleep restriction ranges from a single night (Donga et al., 2010) to two weeks 
(Nedeltcheva et al., 2009). Whilst some studies have shown no change in glucose 
tolerance following sleep restriction (Bosy-Westphal et al., 2008; Schmid et al., 
2009), the majority of studies have demonstrated disruptions in glucose or 
insulin metabolism after reduced sleep.  
Varied results between studies could be due to differences in methodologies. 
Studies often differ in terms of sleep restriction severity, but also differ when 
employing a control condition. Previous studies have employed a control 
condition of a set duration that is likely to be longer than habitual sleep duration 
(for example 10 or 12 h). Since individual habitual sleep duration can differ, this 
raises the question if results can be altered by comparing sleep restriction to a 
control condition which is longer than habitual sleep duration. A recent study 
demonstrated that just two nights of extended sleep can reverse the effects of 
four nights of sleep restriction on glucose regulation (Broussard et al., 2016).  
A large majority of studies have investigated glucose clearance and insulin 
sensitivity following sleep restriction, but less is known about substrate 
oxidation. It would seem plausible that sleep restriction would impair CHO 
oxidation to accompany impaired glucose clearance. However, studies that have 
investigated substrate oxidation following sleep restriction provide conflicting 
findings (St-Onge et al., 2011; Klingenberg et al., 2012; Shechter et al., 2014).  
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Consequently, the purpose of this pilot study was to design a sleep restriction 
protocol which would induce impaired glucose tolerance, accounting for 
individual differences in habitual sleep duration. This pilot study will also 
examine substrate oxidation as well as glucose tolerance following sleep 
restriction. The protocol will examine the impact of two nights of 50% sleep 
restriction under free-living conditions on glucose tolerance and substrate 
metabolism compared to a control condition of habitual sleep. We hypothesise 
that two nights of partial sleep restriction will impair glucose tolerance in healthy 
individuals. 
 
3.2 – Methods 
3.2.1 – Participants 
10 participants were recruited by advertisement from the University to take part 
in this crossover study. Healthy males aged between 18 and 40 yr with a self-
reported regular sleeping pattern were included. Exclusion criteria included the 
presence of any chronic illnesses such as diabetes or a history of any sleep 
disorders such as insomnia. Participants were fully informed of the study 
procedures and written consent was obtained prior to participation. The 
University of Stirling School of Sport Ethics Committee approved the study 
protocol.  
3.2.2 – Experimental protocol 
Prior to each trial participants were provided with a 5-day sleep diary. They were 
instructed to complete the sleep diary every morning for 3 days prior to and the 
2 days during each trial period. The sleep diaries allowed analysis of habitual 
sleep characteristics, as well as being a measure of compliance. The sleep diary 
also asked participants to rate their ‘sleepiness’ on a scale of 1 to 10, with 1 
being the least and 10 being the highest feeling of sleepiness. Participants were 
also asked to avoid caffeine and alcohol during the trial period. 
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The study consisted of a control (CON) trial and sleep restriction (SR) trial, which 
each lasted two consecutive nights. Trials were separated by a period of at least 
one week. During the control condition participants were instructed to go to bed 
and wake at their habitual time, as determined from the sleep diary. Sleep 
duration in the sleep restriction trial was 50% of habitual duration each night. 
Participants slept the second half of the night in SR, continuing to waken at their 
habitual time each morning. This ensured measurements were obtained at the 
same time after wakening in both trials. 
Participants visited the laboratory in a rested and fasted state on the final 
morning in each condition. On arrival at the laboratory stature and body mass 
were measured. Participants rested in the supine position for five minutes before 
a fingerprick blood sample was obtained for analysis of fasting blood glucose. 
RER and REE were then measured for 15 minutes using indirect calorimetry with 
a ventilated hood (Oxycon, CareFusion, Germany). The first 5 minutes of 
measurement were used to allow participants to become accustomed to wearing 
the hood and were therefore not included in the analysis. 
After fasting measures of blood glucose, substrate oxidation and resting energy 
expenditure (REE) were obtained, an oral glucose tolerance test (OGTT) was 
carried out. Participants were given a drink containing 82.5g dextrose mixed with 
300 ml water which they were instructed to consume all at once. Fingerprick 
blood samples were obtained at 15, 30, 45, 60, 90 and 120 min after the drink. 
Samples were immediately analysed for blood glucose using a glucose meter 
(LifeScan OneTouch, UK). Measurements of substrate oxidation and REE were 
also carried out by indirect calorimetry between 20-30, 50-60, 80-90 and 105-
120 min following consumption the drink. 
3.2.3 – Statistical Analysis 
Data were analysed using Minitab V.17 statistical software (Minitab Ltd., United 
Kingdom). Data for participant and sleep characteristics are displayed as mean ± 
SD. Data for blood glucose, RER, and REE are presented as mean ± SEM. Blood 
glucose, RER and REE were analysed using repeated measures ANOVA and where 
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appropriate paired t-tests were carried out post-hoc to identify any differences 
within main effects. Any data which violated the assumption of normality were 
transformed prior to statistical testing. Area under the curve was calculated for 
plasma glucose and REE using the trapezoidal rule. A p-value of less than 0.05 
was used for significance. 
 
3.3 – Results 
3.3.1 – Participant and sleep characteristics  
10 participants completed the study. All participants were 21 years old. Mean 
stature was 184.7 ± 6.1 cm, and mean body mass was 84.5 ± 8.4 kg. The average 
BMI of the participants was 24.8 ± 2.9 kg/m2. 
Habitual sleep duration was 515 ± 53 min, which was similar to sleep duration in 
the control condition (496 ± 39 min, P = .374). Sleep duration was significantly 
lower in SR than CON (496 ± 39 min in CON and 252 ± 18 min in SR, P < .001). 
3.3.2 – Plasma glucose 
Plasma glucose concentrations throughout the OGTT are presented in Figure 1. 
Fasting plasma glucose was significantly lower in SR than CON (5.33 ± 0.12 
mmol/L and 5.00 ± 0.13 mmol/L in CON and SR, respectively; P = .018). Main 
effects of time (P < .001) and trial x time (P= .009) were found and a trend was 
observed for a main effect of trial (P = .069). Plasma glucose was significantly 
higher in SR at 45 min (P = .021) and 90 min (P = .010), and tended to be higher 
at 60 min (P = .093). Plasma glucose peaked at 30 min in CON (8.54 ± 0.40 
mmol/L) and 45 min in SR (9.23 ± 0.46 mmol/L). In both conditions glucose 
concentrations returned close to baseline by 120 min (5.09 ± 0.19 mmol/L in 
CON and 5.17 ± 0.21 in SR)(Figure 1A). Area under the curve for plasma glucose 
was 13% higher in SR than CON (784 ± 20 in CON and 883 ± 32 in SR, P = .001) 
(Figure 1B).  
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Figure 1. Blood glucose concentrations (Fig. A) and glucose AUC (Fig. B) during 
the OGTT following two nights of control sleep (CON) or 50% of habitual sleep 
(SR). (N=10). † indicates a significantly lower glucose concentration in SR than 
CON. * indicates significantly higher value in SR than CON. P < .05 used for 
significance. 
32 
 
3.3.3 – Resting energy expenditure  
No effect of trial or trial x time were observed for REE (P = .497 and P = .539, 
respectively), however there was a main effect of time (P = .006). Fasting REE 
was similar between conditions (1.44 ± 0.04 and 1.48 ± 0.05 kcal/min for CON 
and SR, respectively; P = .324). There was also no difference between conditions 
for AUC (169 ± 5 and 171 ± 4 for CON and SR, respectively; P = .598).  
3.3.4 – Respiratory exchange ratio and substrate oxidation 
Respiratory exchange ratio and CHO and fat oxidation rates during the OGTT are 
displayed in Figure 2. Main effects of trial and time were found for RER (P = .013 
and P < .001, respectively). There was no effect of trial x time (P = .109). Paired t-
tests revealed a significantly lower RER at 30 min in the SR condition (0.85 ± 0.02 
for CON and 0.79 ± 0.01 for SR; P = .001). Trends were also observed at fasting 
and 60 min (P = .050 and P = .060, respectively).  
 Main effects of trial (P = .022) and time (P < .001) were observed for CHO 
oxidation (Fig. 2B). There was a trend for an effect of trial x time (P = .082). 
Paired t-tests revealed a trend for lower fasting CHO oxidation in SR compared to 
CON (0.18 ± 0.03 g/min in CON and 0.10 ± 0.03 g/min in SR, P = .055), and 
significantly lower CHO oxidation in SR at 30 min (P = .007) and 60 min (P = .039). 
Main effects of trial (P = .012) and time (P < .001) were also observed for fat 
oxidation during the OGTT (Fig. 2C), however there was no effect of trial x time 
(P = .836). Fasting fat oxidation tended to be higher in SR than CON (P = .055). 
Paired t-tests also demonstrated significantly higher fat oxidation at 30 min (P = 
.003) and 60 min (P = .037). 
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Figure 2. Respiratory exchange ratio (Fig. 2A), CHO oxidation (Fig. 2B), 
and fat oxidation (Fig. 2C) during OGTT following two nights of 
control sleep (CON) or sleep restriction (SR). N=10. * indicates a 
significantly higher value in SR. † indicates a significantly lower value 
in SR. P < .05 used for significance. 
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3.4 – Discussion  
The aim of this pilot study was to determine whether two nights of 50% sleep 
restriction would impair glucose regulation in young healthy males. The findings 
demonstrate increased blood glucose concentrations in the sleep restriction 
condition compared to the control condition, indicating that two nights of partial 
sleep loss was sufficient to impair glucose tolerance in this population. 
Glucose AUC and peak glucose concentration were both increased in the sleep 
restriction condition compared to the control condition. This increased glucose 
response may be due to reduced insulin sensitivity, which has been observed 
previously (Spiegel et al., 1999). The present study did not measure plasma 
insulin, therefore we can only speculate an altered insulin response. 
Measurement of plasma insulin concentrations would have allowed better 
interpretation of results, therefore future studies should include measurement 
of insulin concentrations to determine whole-body insulin sensitivity. 
Indirect calorimetry measurements showed no change in REE in the fasted state 
or during the OGTT. However, the findings did demonstrate a preference 
towards fat utilisation in the fasted state following sleep loss compared to 
normal sleep, as indicated by decreased respiratory exchange ratio and 
carbohydrate oxidation and increased fat oxidation. 
Resting energy expenditure was not altered by sleep restriction in the present 
study which is in agreement with previous studies (Bosy-Westphal et al., 2008; 
Nedeltcheva et al., 2009; Buxton et al., 2010; St-Onge et al., 2011; Klingenberg et 
al., 2012; Shechter et al., 2014). The only study which observed a change in REE 
was that of Benedict and colleagues (2011), however sleep was deprived for an 
entire night in this study, suggesting that REE may be affected only by total sleep 
deprivation rather than partial restriction. The absence of slow wave sleep in 
total sleep deprivation may explain the discrepancies between studies using 
partial and total sleep deprivation. Slow wave sleep is an important contributor 
to energy conservation during sleep, and is often preserved even when sleep is 
restricted (Brunner et al., 1993; Belenky et al., 2003). It could therefore be 
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speculated that no change was observed in the studies using partial sleep 
restriction as slow wave sleep may not have been significantly less than in 
normal sleep, although without polysomnography to measure sleep architecture 
we cannot be certain this is the case. 
The findings of this study indicate increased utilisation of fat in the fasted state 
after sleep restriction. Similarly, at measurements obtained between 20 and 30 
min and 50 and 60 min during the OGTT, there was increased fat and decreased 
carbohydrate oxidation after sleep restriction compared to control sleep. 
However, this difference was observed only at the first two time points after 
ingestion of the drink, suggesting that the switch in fuel preference may have 
been temporary. Indeed, previous studies have suggested that the decreased 
fasting RER observed after sleep restriction is likely due to the increased time 
spent awake in the fasted state, and does not reflect a true change in substrate 
use (Klingenberg et al., 2012; Shechter et al., 2014). The findings of the current 
study may also be representative of this theory as differences were observed 
only in the fasted state and early stages of the OGTT.  
The length of measurement of REE and RER is a limitation of the present study. 
Although our findings are indicative of reduced carbohydrate oxidation in the 
fasted state and after ingestion of a glucose bolus, it is unknown if this would 
return to normal as the day progresses. A decrease in carbohydrate utilisation is 
typical of ageing individuals and is correlated with a higher body fat percentage 
and increased plasma glucose levels (Rizzo et al., 2005). However, whether the 
reduction in RER in the present study would have any clinical significance long 
term would require a longer period of measurement to determine how long it 
would take for RER values to return to values observed in the control condition.  
This pilot study revealed interesting findings which would benefit from further 
investigation in a more controlled trial. Glucose regulation is impaired in healthy 
individuals following just two nights of sleep restriction. Given that impaired 
glucose regulation is a primary characteristic of type 2 diabetes (American 
Diabetes Association, 2006), arguably one of the most important questions 
raised from this is what is the mediator between sleep loss and impaired glucose 
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regulation? Future research should therefore explore this relationship further in 
an attempt to establish the underlying mechanisms. Developing knowledge of 
the underlying mechanisms may allow development of interventions to alleviate 
this impairment following sleep restriction, and therefore lowering the risk of 
type 2 diabetes. 
The next study in this thesis was designed to extend the current knowledge by 
examining potential underlying mechanisms, specifically systemic inflammation 
and skeletal muscle insulin signalling, which may be responsible for impaired 
glucose tolerance after sleep restriction. 
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Chapter 4 
A potential role of skeletal muscle insulin signalling but no effect of 
inflammation in impaired whole body insulin sensitivity following acute sleep 
restriction in healthy individuals 
4.1 - Introduction 
The link between sleep restriction and poor glucose metabolism is not well 
understood. Reduced insulin sensitivity is thought to be responsible for the 
decrease in glucose tolerance (Donga et al., 2010; Broussard et al., 2012; Rao et 
al., 2015; Wang et al., 2016). Reduced insulin sensitivity has been observed after 
restricting sleep for 1 to 3 hours for 3 nights (Wang et al., 2016). Likewise, a 
single night of sleep restriction is sufficient to reduce insulin sensitivity by up to 
25% (Donga et al., 2010), suggesting that even mild sleep restriction may 
negatively impact glucose metabolism and insulin sensitivity.  
Despite many studies showing an impairment in glucose metabolism and insulin 
sensitivity after sleep restriction, there is a lack of knowledge regarding the 
mechanisms responsible for this impairment. Proposed mechanisms include 
disruption of insulin signalling in peripheral tissues (Broussard et al., 2012; Rao et 
al, 2015) and increased inflammation (Padilha et al., 2011). 
Recent work by Rao and colleagues (2015) demonstrated that 5 nights of 4 h 
sleep led to decreased peripheral, but not hepatic, insulin sensitivity compared 
to 5 nights of 8 h sleep. This work offers insight that the peripheral tissues may 
influence the impairment in glucose metabolism following sleep restriction. 
Consistent with this finding, previous research has revealed an impairment in 
insulin signalling in adipose tissue when whole body insulin sensitivity is reduced 
following sleep loss (Broussard et al., 2012). Given that skeletal muscle accounts 
for up to 80% of glucose uptake under insulin-stimulated conditions (Thiebaud et 
al., 1982), it is possible that skeletal muscle may also exhibit impaired insulin 
signalling and contribute to impaired whole body glucose control after sleep 
restriction. 
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Insulin resistance is often accompanied by increased low-grade inflammation 
(Shoelson et al., 2006). Sleep deprived individuals often display increased levels 
of inflammation (Meier-Ewert et al., 2004; Vgontzas et al., 2004; Irwin et al., 
2006). However, some research has shown conflicting findings, observing 
increases in some but not all inflammatory markers measured (Shearer et al., 
2001). The inconsistent findings suggest a dose-dependent relationship may exist 
between sleep loss and inflammation, therefore whether increased inflammation 
contributes to the impairment in glucose regulation after only two nights of 
sleep restriction is unknown. 
At present, no published studies have investigated the effects of sleep restriction 
on insulin signalling within skeletal muscle, or whether decreased insulin 
sensitivity is coupled with increased inflammation after two nights of partial 
sleep restriction. Therefore, this study was designed to address this gap in the 
literature. The aims of the study were to investigate (a) the effects of two nights 
of sleep restriction on whole body glucose tolerance and insulin sensitivity; (b) 
whether there were any changes in skeletal muscle insulin signalling after sleep 
restriction; and (c) whether any changes in insulin sensitivity were coupled with 
changes in levels of inflammation. We hypothesised that two nights of sleep 
restriction would decrease whole body glucose tolerance and insulin sensitivity, 
as well as increasing systemic inflammation and disrupting insulin signalling 
within skeletal muscle.  
 
4.2 – Methods 
4.2.1 – Participant and Study Design 
Ten participants were recruited by advertisement to take part in this randomised 
crossover trial. The study involved three visits to the laboratory which comprised 
of a pre-screening visit and two main trial visits. The main trial visits were 
separated by a 3 wk washout period. Inclusion criteria were healthy males aged 
18 to 40 yr with a regular sleeping pattern. Exclusion criteria included smokers, 
individuals that have travelled across times zones or carried out shift work in the 
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past four weeks, or individuals who reported any symptoms of poor sleeping 
behaviour. Individuals who reported the presence of any health conditions or 
who were taking any medications that may interfere with or be worsened by the 
study protocol, such as metabolic disorders, were also excluded. The study 
protocol was approved by the local University research ethics committee. All 
participants were fully informed of the study procedures and gave written 
consent prior to participation. 
4.2.2 – Pre-screening  
Participants arrived at the laboratory in the morning for the pre-screening visit. 
Stature and body mass were measured and body mass index was calculated. 
Participants then completed a standard health questionnaire, a morningness-
eveningness questionnaire (Horne and Ostberg, 1976) and the Pittsburgh Sleep 
Quality Index (PSQI) (Buysse et al., 1989) to assess overall health and sleep 
characteristics prior to participation. Each participant was given a 7-day sleep 
diary and 3-day food diary which they were required to complete before the first 
main trial. A wrist watch actigraph (GENEActiv, Activinsights Ltd., 
Cambridgeshire, UK) was worn in conjunction with the 7-day sleep diary to 
obtain an objective measurement of habitual sleep duration.  
4.2.3 – Entraining 
Participants underwent one week of entraining prior to each main trial. During 
this period, participants were instructed to continue with their usual daily 
routines and to go to bed and wake at the same time every day, keeping times 
similar to their habitual sleeping behaviours. Wrist actigraphy was used 
throughout the entraining period to ensure compliance. 
4.2.4 – Trial Conditions 
Trials consisted of two consecutive nights of either control sleep (CON) or 
partially restricted sleep (SR). Control sleep duration was calculated as the mean 
habitual sleep duration determined by the 7-day sleep diary and actigraphy. 
Sleep duration in SR was 50% of the mean habitual sleep duration. During the 
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sleep restriction trial participants slept the second half of the night, continuing to 
wake at the same time each morning. A constant wake time ensured 
measurements were obtained the same length of time after wakening in each 
trial. 
Permuted block randomisation was used to assign participants to the first study 
condition. Six participants completed the control condition first. During both 
trials wrist actigraphy was used to ensure compliance. In addition, in the sleep 
restriction trial participants sent time stamped SMS messages to the researcher 
every hour from their habitual bed time until their sleep restricted bed time. 
During the trials participants were provided with a 48 h diet based on their 
habitual food intake determined from the 3-day food diary. This diet was 
replicated for each trial and participants were instructed to eat only the food 
provided during this period. Participants were asked to continue with their 
normal daily routines during each trial period but to avoid any vigorous physical 
activity or consumption of caffeine or alcohol.  
4.2.5 – Laboratory Visits 
Following the second night of control sleep or sleep restriction, participants 
arrived at the laboratory in a rested and fasted state. After measurement of 
stature and body mass, participants rested in the supine position before blood 
pressure and heart rate were measured using a digital blood pressure monitor 
(Hangzhou Sejoy Electronics & Instruments Co., LTD, China). A cannula was then 
inserted into the antecubital vein in the arm to allow blood samples to be drawn 
regularly. Participants then performed an oral glucose tolerance test (OGTT) to 
assess glucose clearance. Participants were given a drink containing 82.5 g 
dextrose mixed with 300 ml water, which they were instructed to consume all at 
once. Blood samples were collected before (0 min) and at 15, 30, 45, 60, 90 and 
120 min following consumption of the drink. In addition, muscle tissue samples 
were obtained before (0 min) and 30 and 120 min after the ingestion of the 
drink.  
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4.2.6 – Blood collection and processing 
All blood samples throughout the OGTT were obtained by the cannulation 
technique. For each sample 10 ml of blood was collected into EDTA treated and 
untreated vacutainer tubes. After collection, untreated serum samples were left 
at room temperature for 30 min and EDTA treated samples were immediately 
placed on ice. All samples were centrifuged at 3500 rpm for 10 min at 4°C. After 
centrifugation plasma was aliquoted into micro tubes and stored at -70°C until 
analysis. 
4.2.7 – Blood plasma assays 
Blood samples collected at 0, 15, 30, 45, 60, 90 and 120 min during the OGTT 
were analysed for plasma glucose. Plasma glucose was assayed in duplicate using 
an ILab automated analyser (Instrumentation Laboratory, Warrington, Cheshire, 
UK). Circulating insulin was measured at 0, 15, 30, 45, 60, 90 and 120 min using 
ELISA techniques from a commercially available ELISA kit (Demeditec, Kiel, 
Germany). Inflammatory markers were measured from blood samples collected 
at 0, 30 and 120 min during the OGTT also using commercially available ELISA kits 
for TNF-α (Invitrogen, Camarillo, CA) and CRP (Kalon Biological, Guildford, UK).  
4.2.8 – Muscle collection and preparation 
Muscle tissue samples during the OGTT were obtained from the Vastus Lateralis 
using the Bergstrom biopsy technique. The site was cleaned before 2% Lidocaine 
was injected to anesthetise the local area. A tissue sample was then obtained. 
Approximately 60-100 mg of skeletal muscle tissue was obtained for each 
sample. Tissue samples were immediately cleaned with saline solution to remove 
blood and fat tissue. Cleaned samples were placed in micro tubes and snap 
frozen using liquid nitrogen before being transferred to a -70°C freezer, where 
they were stored until analysis. 
4.2.9 – Muscle tissue processing 
Approximately 30 mg of human skeletal muscle tissue was homogenized by a 
dounce homogeniser on ice in RIPA buffer [50 mmol/l Tris·HCl pH 7.5, 50 mmol/l 
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NaF, 500 mmol/l NaCl, 1 mmol/l sodium vanadate, 1 mmol/l EDTA, 1% (vol/vol) 
Triton X-100, 5 mmol/l sodium pyrophosphate, 0.27 mmol/l sucrose, and 0.1% 
(vol/vol) 2-mercaptoethanol and Complete protease inhibitor cocktail (Roche)]. 
Debris was removed by centrifugation at 4°C for 15 min at 13,000 g. The 
supernatant was then removed, and protein concentration was determined 
using the bicinchoninic acid protein assay according to the manufacturer's 
instructions (Sigma Aldrich, UK). 
4.2.10 – Kinase assay 
PanPKB kinase assays were carried out by immunoprecipitation for 2 h at 4°C in 
homogenization buffer [50 mM Tris·HCl pH 7.5, 0.1 mM EGTA, 1 mM EDTA, 1% 
(vol/vol) Triton X-100, 50 mM NaF, 5 mM NaPPi, 0.27 M sucrose, 0.1% β-
mercaptoethanol, 1 mM Na3(OV)4, and 1 Complete (Roche) protease inhibitor 
tablet per 10 ml]. Protein G sepharose (2.5 μl per IP) was used to precipitate the 
immune complexes. Immune complexes were washed twice in high-salt washes 
(homogenisation buffer as above with 0.5 M NaCl added) followed by one wash 
in assay buffer (see below). Prior to carrying out the activity assay the immune-
bead-complex was suspended in a total of 10 μl of assay buffer. All assays were 
carried out in a 50-μl reaction. Assays were started every 20 s by the addition of 
a hot assay mix, which consisted of assay buffer (50 mM Tris·HCl pH 7.4, 0.03% 
Brij35, and 0.1% β-mercaptoethanol), ATP-MgCl2 (100 μM ATP + 10 mM 
MgCl2), 
32γ-ATP (specific activity; 0.5 × 106 cpm/nmol), and finally synthetic 
peptide substrates (Crosstide; GRPRTSSFAEG at 30 μM). Assays were stopped at 
20-s intervals by spotting onto squares of p81 chromatography paper (Whatman; 
GE Healthcare, UK) and immersing in 75 mM phosphoric acid. Papers (p81) were 
washed three times for 5 min in 75 mM phosphoric acid and once in acetone. 
They were then dried and immersed in Gold Star LT Quanta scintillation fluid 
(Meridian Biotechnologies, Chesterfield, UK) and counted in a Packard 2200CA 
TriCarb scintillation counter (United Technologies). Assay results were quantified 
in nmol·min−1·mg−1 (U/mg). Blanks for background subtractions were carried out 
with immunoprecipitated kinases with no peptide included in the assay reaction. 
Activities assays for panPKB were carried out on cell lysates by IP from 300 μg of 
43 
 
cell lysate. The IP step was performed with 2 μg each of PKBα/β/γ antibodies 
(DSTT, Dundee University). Antibodies were used with 2.5 μl of protein G 
sepharose per IP to immunoprecipitate for 2 h at 4°C. The activity assay ran for 2 
hr. 
4.2.11 – Western blots 
Protein was boiled in Laemmli sample buffer and separated on SDS-PAGE gels for 
1.5 h at 150 V. Proteins were then transferred to PDVF membranes for 2 h at 30 
V. Following transfer membranes were blocked for 1 h in BSA solution. 
Membranes were then incubated overnight at 4°C with the appropriate primary 
antibody diluted in TBST. Primary antibodies were phosphoPKB Thr308, total Akt 
and eEf2 (Cell Signalling). The membranes were rinsed three times for 5 min in 
TBST the next morning before being incubated with HRP-conjugated anti-rabbit 
secondary antibody (Cell Signalling) diluted in TBST. The membranes were 
washed three times for 5 min with TBST. Enhanced chemiluminescence was used 
to detect antibody binding. Band visualisation was carried out using a Chemidoc 
XRS system (Bio-Rad, Hertfordshire, UK). Bands were quantified by densitometry 
(Image Lab, Bio-Rad, Hertfordshire, UK). Membranes were stripped using 
stripping buffer and re-probed for total protein to express phosphoprotein 
relative to total protein.  
4.2.12 – Statistical analysis 
Data were analysed using Minitab v.17 statistical software (Minitab Ltd., United 
Kingdom). Participant characteristics and sleep time are presented as mean ± SD. 
Blood variables and muscle PKB data are presented as mean ± SEM. Repeated 
measures ANOVA (trial x time) were employed to analyse plasma glucose, insulin 
and inflammatory markers and muscle PKB phosphorylation and activity. Paired 
t-tests were carried out post-hoc to identify any differences in main effects and 
at 0 min for each variable to compare baseline values. Data which violated the 
assumptions of the statistical tests were transformed appropriately prior to 
analysis. A p-value of less than 0.05 was used to indicate significance. The 
Matsuda Index (Matsuda and DeFronzo, 1999) and homeostasis model 
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assessment (HOMA) (Matthews et al., 1985) were used to estimate insulin 
sensitivity. Area under the curve for glucose, insulin, inflammatory markers, PKB 
activity, and PKB phosphorylation were calculated using the trapezoidal rule and 
the area under the curve for plasma insulin to PKB activity ratio was determined. 
Cohen’s d effect sizes and confidence intervals were calculated for PKB activity.  
 
4.3 – Results 
4.3.1 – Participant and Sleep Characteristics 
Ten males completed the study. Participant characteristics are displayed in Table 
1. Habitual time to bed ranged from 2120 h to 0245 h, with a mean time to bed 
of 2344 h. Participants’ habitual wakening time was between 0544 h and 1020 h, 
with an average time of 0742 h. Mean habitual sleep duration was 484 ± 66 min. 
Mean sleep duration in the control condition was 442 ± 78 min, which was not 
significantly different from habitual sleep duration (P = .124). Mean sleep 
duration in SR was significantly less than in CON (235 ± 34 min for SR; P < .001). 
Mean time to bed and mean wakening time was 2349 h and 0711 h in CON and 
0319 h and 0714 h in SR, respectively. 
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Participant Characteristics 
Age (yr) 23 ± 4 
Stature (cm) 181.6 ± 5.8 
Body mass (kg) 82.2 ± 9.5 
Body mass index (kg/m2) 24.9 ± 2.1 
Systolic blood pressure (mmHg) 125 ± 5 
Diastolic blood pressure (mmHg) 70 ± 4 
Habitual energy intake (kcal/d) 2369 ± 616 
PSQI score  4 ± 1 
Morningness-eveningness score 53 ± 8 
Table 1. Participant characteristics at baseline. Data presented as mean ± SD. N=10. PSQI 
= Pittsburgh Sleep Quality Index. PSQI score equal to or greater than 5 is indicative of 
poor sleep quality. Morningness-eveningness score can range from 16 (‘definite evening 
type’) to 86 (‘definite morning type’). A score of 42-58 is indicative of ‘neither type’. 
4.3.2 – Plasma glucose and insulin 
Mean plasma glucose and insulin concentrations during the OGTT and area 
under the curve for plasma glucose and insulin are displayed in Figure 3. A 
repeated measures ANOVA revealed a main effect of time for plasma glucose (P 
< .001). There was no effect of trial (P = .222) or trial x time (P = .985). Mean 
baseline plasma glucose concentrations during CON were similar to SR (4.92 ± 
0.10 mmol/L and 5.02 ± 0.06 mmol/L, respectively; P = .221). In response to the 
dextrose drink, plasma glucose peaked at 45 minutes in both conditions (7.69 ± 
0.75 mmol/L and 8.57 ± 0.69 mmol/L for CON and SR, respectively). Plasma 
glucose returned to values similar to baseline at 120 min in both conditions (5.55 
± 0.37 mmol/L and 5.85 ± 0.30 mmol/L for CON and SR, respectively). Similarly, 
AUC was not different between conditions (P = .391).  
Mean plasma insulin concentrations showed main effects of trial and time during 
the OGTT (P = .006 and P < .001, respectively). Plasma insulin values were similar 
at baseline in CON and SR (18.7 ± 4.9 µIU/mL and 20.0 ± 5.0 µIU/mL, 
respectively; P = .172). In response to the dextrose drink plasma insulin peaked 
at 60 min in CON and at 45 min in SR (69.0 ± 12.5 µIU/mL at 60 min in CON and 
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83.9 ± 10.2 µIU/mL at 45 min in SR). SR displayed significantly higher insulin 
concentrations than CON at 15 min (59.1 ± 9.0 µIU/mL and 48.5 ± 9.5 µIU/mL for 
SR and CON, respectively; P = .031) and at 45 min (83.9 ± 10.2 µIU/mL and 67.3 ± 
10.8 µIU/mL for SR and CON, respectively; P = .028). During the OGTT there was 
a 14% higher insulin AUC in the sleep restriction condition compared to the 
control (7069 ± 1018 vs. 8068 ± 901 for CON vs. SR, respectively; P = .013). 
Matsuda Index was 18.6% lower in SR than CON (4.19 ± 0.71 vs. 3.41 ± 0.51 for 
CON and SR, respectively; P = .010). There was no difference in HOMA between 
conditions (4.05 ± 1.02 and 4.42 ± 1.08 for CON and SR, respectively; P = .139). 
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Figure 3. Mean plasma glucose and insulin concentrations during the OGTT following two 
nights of normal sleep (CON) or sleep restriction (SR) (n=10). (A) Mean plasma glucose 
concentrations for CON and SR. (B) Area under the curve for plasma glucose. (C) Mean 
plasma insulin concentrations for CON and SR. (D) Area under the curve for plasma 
insulin. (E) Matsuda Index calculated from 0, 30, 60, 90 and 120 min during the OGTT. (F) 
Homeostasis model assessment (HOMA). * indicates significantly higher values in SR 
condition. † indicates significantly lower values in SR condition. P<0.05 was used to 
indicate significance. 
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4.3.3 – Plasma inflammatory markers 
Concentrations of circulating CRP and TNF-alpha are displayed in Table 2. CRP 
data was unavailable for one participant, therefore n=9 for CRP results. A trend 
for a main effect of trial was observed for CRP (P = .094), however there was no 
effect of time (P = .685) or trial x time (P = .537). CRP at baseline tended to be 
lower in SR than CON (P = .092), however this trend was no longer visible at 120 
min (P = .202). An analysis of variance revealed no effect of trial (P = .421), time 
(P = .912), or trial x time (P = .697) for TNF-α. Similarly, there was no difference in 
baseline concentrations of TNF-α between conditions (P = .858). 
 
Inflammatory marker CON SR 
CRP (mg/L) 
0 min 
120 min 
 
1.6 ± 0.3 
1.6 ± 0.2 
 
0.8 ± 0.2 
1.0 ± 0.2 
TNF-α (pg/ml) 
0 min 
120 min 
 
1.82 ± 0.06 
1.81 ± 0.04 
 
1.84 ± 0.05 
1.83 ± 0.06 
Table 2. Circulating inflammatory markers before (0 min) 
and 120 min during an OGTT following two nights of control 
sleep (CON) or sleep restriction (SR). Data presented as 
mean ± SEM. N = 9 for CRP and N = 10 for TNF-α. 
 
4.3.4 – Skeletal muscle insulin signalling 
PanPKB Activity 
PanPKB activity is shown in Figure 4. One participant was excluded from the 
results for PKB activity due to analysis problems, therefore, n=9 for all panPKB 
activity results. A main effect of time was observed for panPKB activity (P = .001) 
and there was a trend for trial x time (P = .087). There was no effect of trial (P = 
.589). PanPKB activity (Fig. 4A) during CON was 12.37 ± 1.93 µU/min/mg at 
baseline and was significantly increased in response to the dextrose drink at 30 
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min (26.67 ± 4.96 µU/min/mg; P = .007) and 120 min (21.47 ± 2.75 µU/min/mg; P 
< .001). At baseline panPKB was 27% higher in SR than CON, demonstrating a 
medium effect size (15.72 ± 1.81 µU/min/mg in SR; 95% CI -1.91, 8.61; Cohen’s d 
= 0.63). PanPKB in SR displayed a 16% lower response than CON at 30 min, 
showing a small effect size (22.29 ± 4.88 µU/min/mg at 30 min in SR; 95% CI -
9.60, 0.85; Cohen’s d = 0.32). PanPKB activity was similar between conditions at 
120 min (21.47 ± 2.75 µU/min/mg and 21.40 ± 2.69 µU/min/mg for CON and SR, 
respectively; Cohen’s d=0.01). 
PanPKB fold change (Fig. 4B) from baseline to 30 min tended to be lower in SR 
than CON (2.7 ± 0.7 fold in CON and 1.5 ± 0.3 fold in SR; 95% CI -2.91, 0.65; P = 
.098, Cohen’s d = 0.69). Likewise, there was a tendency for a lower fold change 
from baseline to 120 min in SR than CON, displaying a large effect size (1.9 ± 0.2 
fold in CON and 1.4 ± 0.1 fold in SR; 95% CI -1.03, 0.04; P = .087; Cohen’s d = 
1.08). 
The area under the curve for plasma insulin to PKB activity index ratio is 
displayed in Figure 4C. AUC for plasma insulin:PKB activity index was 2.67 ± 0.51 
in CON and was significantly greater in SR at 3.33 ± 0.48 (95% CI 0.19, 1.14; P = 
.012, Cohen’s d = 0.47). 
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Figure 4. panPKB activity during the OGTT following two nights of normal sleep (CON) or 
sleep restriction (SR) (n=9). (A) panPKB activity at each timepoint. (B) Fold change from 
baseline in panPKB activity at 30 and 120 minutes. (C) AUC Insulin:PKB index. * indicates 
a significant difference between conditions. P<0.05 used for significance. 
A 
B 
C 
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PKB phosphorylation 
PKB phosphorylation results are displayed in Figure 5. No main effects of trial or 
trial x time were observed for phosphorylated to total PKB (P = .217 and P = .845, 
respectively), however there was a main effect of time (P = .007). The AUC for 
phosphorylated to total PKB ratio (Fig. 5B) was similar between conditions (274 ± 
69 in CON and 296 ± 50 in SR; P = .433). 
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Figure 5. PKB phosphorylation during OGTT following two nights of control sleep 
(CON) or sleep restriction (SR) (n=9). (A) Blot showing phosphorylated (pPKB) and 
total (tPKB) PKB. Bar graph demonstrates phosphorylated to total PKB ratio at 0, 30, 
120 min following OGTT. (B) AUC for phosphorylated to total PKB during OGTT. 
B 
A 
pPKB 
tPKB 
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4.4 – Discussion 
The current study aimed to investigate if the reduction in insulin sensitivity 
observed after sleep restriction is coupled with any changes in skeletal muscle 
insulin signalling and whole body inflammation. The findings confirm that two 
nights of sleep restriction reduced whole body insulin sensitivity. However, 
contrary to the hypothesis, systemic inflammation did not increase, as shown by 
measurements of circulating CRP and TNF-α. Findings regarding skeletal muscle 
insulin signalling are conflicting. The PKB kinase assay results point towards a 
reduction in PKB activity following sleep restriction. However, Western blot 
analysis demonstrated no differences in phosphorylation of PKB between 
conditions. Collectively, these findings demonstrate that two nights of 50% sleep 
restriction impairs whole body insulin sensitivity in healthy males, and that this 
impairment does not seem to be caused by increased inflammation, 
contradicting what has been suggested previously. It is still unclear whether a 
defect in skeletal muscle is a contributing factor or not, although some of our 
findings suggest the presence of mild changes in skeletal muscle insulin signalling 
after sleep restriction which may be responsible for the observed impairment. 
Plasma glucose concentrations were unchanged following sleep restriction in the 
current study. Fasting plasma glucose was similar between the sleep restriction 
and control condition, which is consistent with previous studies (Donga et al., 
2010; Schmid et al., 2009; Schmid et al., 2011; Reynolds et al., 2012; Rao et al., 
2015; Wang et al., 2016). Likewise, during the OGTT, plasma glucose 
concentrations were comparable between conditions. Several other studies have 
also found no changes in plasma glucose following sleep restriction (Zielinski et 
al., 2008; Schmid et al., 2009; Rao et al., 2015; Wang et al., 2016). However, 
others have observed altered glucose metabolism after sleep restriction (Spiegel 
et al., 1999; Nedeltcheva et al., 2009; Buxton et al., 2010; Reynolds et al., 2012). 
While it is unknown why there are differences between studies, the severity of 
sleep loss may explain the differences between findings. Those studies that have 
demonstrated changes in glucose metabolism after sleep loss utilised a more 
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severe sleep restriction protocol than those studies that observed no changes, 
including the current study. It is not known if a dose-response relationship 
between sleep restriction and impaired glucose metabolism exists; whilst it 
seems likely, it has not been confirmed, therefore additional research in this area 
is required. Often studies have compared sleep restriction to an extended 
duration of sleep beyond the recommended 7 to 9 hours and used a fixed 
duration of sleep restriction for all participants. Using such a sleep restriction 
protocol limits the applicability of the findings as individual variations in habitual 
sleep durations may influence how the individuals react to the conditions. 
The plasma glucose findings in the current study also differ from the pilot study 
presented in the previous chapter of this thesis. Plasma glucose was significantly 
higher in the pilot study, whereas no significant changes were demonstrated in 
this study. An important difference between studies was the blood sampling 
method used. The sample size in the current study was small and may be 
underpowered to detect any changes in plasma glucose when venous blood 
sampling is used, which could explain the discrepancies between studies. Despite 
no significant increase in plasma glucose in this study, the peak plasma glucose 
concentration was almost 1 mmol/L higher in the sleep restricted condition 
compared to the control condition, which may still be of physiological 
importance. 
The present study demonstrates increased plasma insulin concentrations and 
area under the curve during the OGTT in the sleep restriction condition 
compared to the control condition. This finding is consistent with previous 
studies (Buxton et al., 2010; Donga et al., 2010; Broussard et al., 2012; Rao et al., 
2015; Wang et al., 2016). The increased plasma insulin response to the drink in 
the sleep restriction condition was not accompanied by any changes in plasma 
glucose, indicating a reduction in whole body insulin sensitivity. Supporting this, 
we observed a lower Matsuda index value in the sleep restriction condition 
compared to the control condition. HOMA, which primarily reflects hepatic 
insulin sensitivity in the fasted state (Abdul-Ghani et al., 2007), was unchanged 
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following sleep restriction, suggesting that the impairment stems from the 
peripheral, rather than hepatic, tissues. 
Sleep restriction has been shown to alter insulin sensitivity in peripheral tissues 
(Broussard et al., 2012; Rao et al., 2015). Given this evidence, the present study 
investigated whether a disruption in skeletal muscle insulin signalling was 
responsible for the impairment in glucose regulation after sleep restriction. 
Assessment of PKB activity did not reveal any statistically significant differences 
between the sleep restriction and control condition; however, a lower fold 
change from baseline at 30 min and 120 min during the OGTT was observed, 
pointing towards a defective response to an oral glucose load. A lower insulin 
signalling response to glucose intake combined with increased circulating insulin 
revealed an increase in the AUC insulin:PKB index after sleep restriction 
compared to control sleep. An increased AUC insulin:PKB index may be indicative 
of reduced insulin sensitivity. Reduced PKB activity in skeletal muscle is often 
noted in individuals with type 2 diabetes (Krook et al., 1998). Although the 
changes in PKB activity in the present study are limited, we speculate that this 
initial defect may lead to comparable changes if continued over a longer period.  
Despite observing small differences in PKB activity, no changes were observed in 
phosphorylation of PKB relative to total PKB content. This finding contradicts the 
results from Broussard and colleagues (2012) who demonstrated a reduction in 
phosphorylated PKB in adipose tissue following sleep restriction. It is unclear why 
there are differences between the studies. One possible reason could be a 
difference in insulin sensitivity between peripheral tissues. However, it is also 
useful to note that Broussard and colleagues used a five night sleep restriction 
protocol, while we employed only two nights of sleep restriction. As mentioned 
previously, it may be that sleep restriction exerts cumulative effects on insulin 
signalling in peripheral issues. If a dose-response relationship between reduced 
PKB phosphorylation and sleep restriction exists, changes may not have been as 
severe in this study.  
Our findings show a discrepancy between Western blot analysis and panPKB 
activity. The findings from activity assays point towards small changes in skeletal 
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muscle insulin signalling, whereas no changes were detected using western blot 
analysis. Discrepancies in results between the activity assay and western blot 
methods assessing protein signalling have been shown previously (McGlory et 
al., 2014). The protein kinase assay method may be able to detect changes of a 
smaller magnitude or in smaller sample sizes compared to the Western blot 
method. Therefore, it is possible that changes in PKB phosphorylation may be 
detected if sleep restriction is more severe either in the number of nights or 
length of restriction each night.  
The current study assessed concentrations of circulating CRP and TNF-α, which 
are representative of whole body inflammation. Taking into consideration the 
findings of previous studies, one hypothesis of the current study was that an 
increase in whole body inflammation would be present following sleep loss. 
However, in contrast to previous research (Meier-Ewert et al., 2004; Vgontzas et 
al., 2004; Irwin et al., 2006), the findings do not support this hypothesis. Similar 
to the plasma glucose findings, it seems likely that a dose-response relationship 
may exist between sleep restriction and whole body inflammation. Two of the 
three studies that observed increased inflammation employed a more severe 
sleep restriction protocol, with at least six nights of restriction (Meier-Ewert et 
al., 2004; Vgontzas et al., 2004). In the study which employed only a single night 
of sleep restriction (Irwin et al., 2006), increased monocyte expression of 
inflammatory markers was observed immediately after wakening. However, this 
change was not present later in the day, suggesting that the difference may have 
only been temporary rather than a true reflection of changes in whole body 
inflammation. Thus, it seems highly plausible that a dose-response relationship 
exists, and that in the present study whole body inflammation was not 
responsible for the impairment in insulin sensitivity. 
To summarise, the findings of the present study indicate that two nights of 50% 
sleep restriction impairs whole body insulin sensitivity in healthy, young males. It 
is unlikely that this impairment is caused by whole body inflammation, however 
skeletal muscle insulin signalling may be a potential contributor. The findings of 
this study have implications for those individuals who voluntarily curtail sleep as 
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the impairment in insulin sensitivity from sleep restriction may increase the risk 
of developing type 2 diabetes. Additional research is therefore warranted to 
clarify the underlying mechanisms leading to the disruption in glucose regulation 
after sleep restriction. 
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Chapter 5 
Summary 
5.1 – General discussion 
The findings presented throughout this thesis clearly demonstrate a disruption in 
whole body metabolism after two nights of sleep restriction, confirming the 
relationship between sleep and glucose metabolism (Morselli et al., 2010). 
However, consistent with earlier studies (Bosy-Westphal et al., 2008; 
Nedeltcheva et al., 2009; Buxton et al., 2010; St-Onge et al., 2011; Klingenberg et 
al., 2012; Shechter et al. ,2014), sleep restriction does not appear to alter resting 
energy expenditure. An increased preference towards fat utilisation was 
observed in the fasted state and early stages of the OGTT in the sleep restricted 
condition but, as suggested previously, this may be due to the increased time 
spent awake in the fasted state, rather than reflecting a true change in substrate 
metabolism (Klingenberg et al., 2012; Shechter et al., 2014). 
The research presented in this thesis has expanded on the existing knowledge by 
exploring the underlying mechanisms leading to impaired glucose regulation 
after sleep restriction. Markers of inflammation and skeletal muscle insulin 
signalling were investigated as potential mechanisms. The findings suggest that 
whole body inflammation is unlikely to play a role in this situation as insulin 
sensitivity was impaired despite no increase in the concentration of circulating 
TNF-α or CRP. The notion that impaired skeletal muscle insulin signalling is a 
potential mechanism is uncertain as PKB signalling within skeletal muscle 
demonstrated conflicting findings, depending on the method of analysis. There 
also appears to be a discrepancy between studies when examining potential 
underlying mechanisms. Hence, it can be proposed that the mechanisms leading 
to impaired glucose regulation after sleep restriction are likely multi-factorial and 
may differ due to factors such as specific tissue insulin sensitivity, method of 
analysis and the length of sleep restriction employed.  
A key strength of the studies presented here is the sleep restriction protocol 
utilised. Many previous studies have employed an absolute duration for the 
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control and sleep restriction conditions. Furthermore, previous studies often 
used extended durations as a control condition, such as 10 or 12 h (Buxton et al., 
2010; Reynolds et al., 2012). Individual habitual sleep duration will differ, which 
may impact results. We overcame this limitation by using a sleep duration close 
to habitual duration in the control condition, and restricted sleep relative to 
habitual duration in the sleep restriction condition. Each individual therefore 
experienced a similar degree of sleep restriction compared to their habitual sleep 
patterns. 
The findings presented in this thesis provide novel insights into the mechanisms 
underlying the impairment in insulin sensitivity following acute sleep restriction. 
However, there are several limitations to the studies presented here which 
should be considered. Firstly, the study samples consisted of only white males. 
Glucose regulation is known to vary between individuals of different ethnicities 
(Osei and Schuster, 1994) and sex (Varlamov et al., 2015), thus findings cannot 
be generalised to other populations due to possible metabolic variations. 
Secondly, sleep patterns were measured by actigraphy which, although validated 
against PSG for overall sleep duration (Jean-Louis et al., 2001), cannot give as 
much detail about sleep architecture as would be given by PSG. Therefore, the 
effect of sleep restriction on sleep quality and individual sleep stages cannot be 
determined. Lastly, the OGTT is an indirect measurement of insulin sensitivity. 
Although the OGTT correlates well with the gold standard hyperinsulinemic- 
euglycemic clamp for overall insulin sensitivity and glucose tolerance, it cannot 
give precise detail about the nature of insulin resistance. 
The findings of these studies have implications for individuals who voluntarily 
curtail sleep, perhaps because of work or social pressures. Impaired insulin 
sensitivity and hyperglycemia are risk factors for the development of type 2 
diabetes. Insulin resistance within skeletal muscle is thought to be the initial 
defect in the development of type 2 diabetes (DeFronzo and Tripathy, 2009). 
Therefore, frequent or prolonged periods of sleep restriction may have 
deleterious effects on glucose regulation, possibly leading to the development of 
type 2 diabetes.  
60 
 
It is questionable that impaired glucose regulation following short, infrequent 
periods of sleep restriction has any clinical relevance. Evidence demonstrates 
that following sleep restriction by periods of catch-up sleep of extended duration 
may attenuate the effects of sleep restriction on glucose metabolism (Killick et 
al., 2015). Similarly, napping in the day following the night of sleep restriction 
may also be beneficial in alleviating the increase in inflammation which has been 
shown after sleep loss (Vgontzas et al., 2007). Thus, the increased risk of 
developing impaired glucose tolerance or type 2 diabetes after sleep restriction 
may be more applicable to chronically sleep-deprived individuals who do not 
repay their sleep debt by extended sleep or naps. 
5.2 – Future study 
The findings of the study presented in this thesis taken together with the existing 
literature identifies several areas which would benefit from further investigation. 
A dose-response study is needed to identify whether there is a cumulative effect 
of sleep restriction on impaired glucose regulation. Further exploration into the 
underlying mechanisms is also warranted, particularly surrounding the possibility 
of disrupted insulin signalling within skeletal muscle. Skeletal muscle insulin 
signalling findings in the present study were inconsistent, and the sample size 
was small, therefore replication of a similar protocol with a larger sample size is 
warranted. 
Interventions to prevent impaired insulin sensitivity following sleep restriction 
are also needed. Exercise is one possible intervention which should be explored. 
Glucose regulation is improved by exercise and this effect can last up to 24 hr 
(Koopman et al., 2005), suggesting that a bout of exercise prior to sleep 
restriction may counteract the effect of sleep restriction on glucose regulation. If 
exercise proves successful in attenuating the impairment in insulin sensitivity 
after sleep loss, it may be used as a possible therapy for shift workers and others 
who experience sleep loss.  
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5.3 – Conclusion  
To conclude, the work presented in this thesis provides novel information which 
aids our understanding of the mechanisms responsible for impaired insulin 
sensitivity following acute sleep restriction. Many questions have been raised 
throughout which give scope for future research. Arguably the most important of 
these are: (a) what are the mechanisms responsible for the impairment? and (b) 
how can we prevent the impairment in insulin sensitivity in situations where 
sleep restriction is unavoidable? So, whilst our work has built on current 
knowledge in the field, there is still much to learn regarding sleep loss and its 
effect on glucose regulation. 
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Appendices 
 
Appendix 1 – Individual Western Blot results showing phosphorylated PKB 
(pPKB) and total PKB (tPKB) in skeletal muscle at 0, 30 and 120 min during an 
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OGTT following two nights of control sleep (CON) or sleep restriction (SR).  
 
 
 
